People with extreme nearsightedness, or myopia, may experience myopic macular degeneration (MMD). This condition can lead to a gradual decrease in central vision.
In people with myopia, the distance between the front and back of each eye is greater than average. This increased eyeball size makes it harder to focus on objects in the distance. Some people with this condition may be at greater risk of developing other eye conditions.
This article will review all there is to know about MMD, from signs and symptoms to the latest research.
MMD, also called degenerative myopia, is the leading cause of legal blindness.
The macula is a tiny region located in the center of the retina. When the retina stretches in people with myopia, it can cause the cells in the macula to degenerate.
If damage occurs to cells in the macula, individuals may experience a blind spot in their central vision. The resulting condition is called MMD.
The causes of MMD vary between individuals.
Excessive stretching can change the arrangement of photoreceptors within the eye. This can impact vision even before degeneration begins.
Changes in certain proteins can also occur as a result of eyeball elongation. Atypical collagen proteins, for example, can lead to a weaker eye structure and cause retinal degeneration.
Additionally, researchers believe that inflammatory conditions may contribute to MMD. Chronic inflammation in the eye tissue may further alter eye structure and function.
Although research links macular degeneration and myopia, not all people with myopia will experience macular degeneration.
During the early stages of MMD, people may experience few, if any, symptoms. A blurry spot in the central vision may eventually appear and worsen with time.
Other common symptoms may include:
People who experience unexpected vision changes should consult an eye specialist.
Changes in central vision, gray or blurry spots, or having trouble reading and recognizing people may all indicate MMD.
A specialist will perform a thorough exam and diagnostic tests to determine whether a persons symptoms indicate MMD. They can then discuss the individuals outlook and treatment options.
People with MMD may experience complications. For example, damage to the retina or scarring in the macula tissue may occur. MMD can lead to blindness in severe cases.
Individuals who receive a diagnosis of MMD should consult with a doctor to prevent any potential complications.
Each case of MMD is unique, and only a medical professional can provide an accurate assessment.
Older individuals and people with very severe myopia have a higher chance of developing MMD.
Research from 2022 suggests that genetics and a persons environment can play a role in the development and severity of myopia. A family history of myopia increases an individuals risk of nearsightedness. A person can also inherit changes to genes involved in eyesight.
Additionally, research indicates that spending more time outdoors helps prevent myopia and that modern, urban lifestyles may put individuals at risk of developing myopia and MMD.
There is currently no single cure for MMD. However, several different treatment options may help prevent vision loss among those who develop this condition.
People with MMD usually develop new blood vessels under the retina. These blood vessels can leak and worsen the effects of MMD. One of the most common treatments involves anti-vascular endothelial growth factor (anti-VEGF) injections. Anti-VEGF drugs may reduce new blood vessel growth, improve vision, and slow macular thickening.
Research also indicates that photodynamic therapy may help treat MMD. Read more about laser therapy for macular degeneration here.
A possible surgical procedure is posterior scleral reinforcement (PSR). The main objective of PSR is to slow down axial elongation, which occurs with myopia.
No one treatment protocol is right for everyone. Individuals with MMD should speak with a medical professional to explore the best treatment options for their unique case.
Managing myopia early in life can help reduce the risk of developing MMD. Possible ways to do this include avoiding exposure to screens and emphasizing time spent outdoors.
Other treatments, such as atropine eye drops, can also help decrease myopia progression in children.
In mild cases of myopia, eyeglasses or contact lenses can improve eyesight. People with more severe myopia may elect to have surgery.
Consistent, thorough eye exams can help detect vision changes early. Eye specialists recommend people with severe myopia and MMD have eye exams every year or more frequently if needed.
During an eye exam, a specialist can ensure that the eyes function correctly. They can also monitor any vision changes that develop gradually.
Individuals with severe myopia may be at greater risk for MMD. This condition can lead to vision changes or, in extreme cases, blindness.
Managing myopia early in life can help reduce the risk of developing MMD. Routine eye examinations with a specialist can also help detect vision problems in their earliest stages.
People who experience myopia should work with a medical professional to manage and monitor their condition over time. Consistent medical support can help manage myopia and reduce the long-term effects of MMD.
Read the rest here:
Myopic macular degeneration: What it is, and more - Medical News Today
- Eye exercises for vertigo: Exercises to try at home - Medical News Today - January 6th, 2023
- EMDR therapy: Everything you need to know - Medical News Today - December 28th, 2022
- Eye floaters: What causes them, and what can you do? - Medical News Today - December 28th, 2022
- Eye care professional - Wikipedia - December 28th, 2022
- New gene therapy to treat rare eye disease now available in Alberta ... - December 28th, 2022
- Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol - PR Newswire - August 11th, 2022
- New research digs into the genetic drivers of heart failure, with an eye to precision treatments - STAT - August 11th, 2022
- Gamma Probe Device Market Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2031 - BioSpace - August 11th, 2022
- Babies born exposed to opioids and drugs need our support - GoErie.com - August 3rd, 2022
- Centrifuge Market: Increasing Prevalence of Infectious Diseases to Drive the Market - BioSpace - August 3rd, 2022
- Roche Wraps Week with a Bang, Touting Long-Term Breast Cancer, AMD Data - BioSpace - July 17th, 2022
- EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment... - July 17th, 2022
- What Are These Things Floating in Front of My Eyes? - The Epoch Times - July 17th, 2022
- Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022... - July 17th, 2022
- Retinoblastoma among children: Early detection and treatment are vital - The Financial Express - May 20th, 2022
- Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs - PR Newswire - May 20th, 2022
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 -... - May 20th, 2022
- How the Pandemic is Taking a Toll on Rhode Island's Front-Line Health Care Workers - Rhode Island Monthly - May 20th, 2022
- Myrtelle Enters into a Worldwide Exclusive License Agreement with Rescue Hearing to Develop and Commercialize Gene Therapy for the Treatment of... - May 20th, 2022
- Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT - BioSpace - May 20th, 2022
- GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of... - May 20th, 2022
- How Diabetes can be a driver for High blood pressure and eventually leads to Hypertension - APN News - May 20th, 2022
- Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative - Yahoo Finance - April 11th, 2022
- Christian group prepares legal challenge over conversion therapy ban - The Telegraph - April 11th, 2022
- PFE: 5 Global Healthcare Stocks to Buy as BofA Warns of a - StockNews.com - April 11th, 2022
- Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the... - April 11th, 2022